Phase 2CompletedAge-related condition

Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen

Study of Vasomotor Symptoms in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen

Sponsor
Eli Lilly and Company (Industry)
Enrollment
150 planned
Conditions
Vasomotor Symptoms; Endometrial Safety
Interventions
Raloxifene; medroxyprogesterone acetate; estrogen; 17 beta estradiol
Ages
adults, older adults
Registry
NCT00332553

Full record on ClinicalTrials.gov

From the registry

This pilot study was designed to explore the effects of combined treatment with raloxifene HCl 60 mg and oral 17 beta-estradiol 1mg/day on the number of vasomotor episodes (hot flashes plus night sweats) in postmenopausal women discontinuing continuous combined hormone replacement therapy (ccHRT) compared to women treated with raloxifene HCl 60 mg alone.

Primary outcomes

  • Compare the number of vasomotor symptoms at 12 weeks between those women taking the combination of raloxifene with oral estradiol versus those taking raloxifene alone.

History

  1. Last registry update

  2. Registered

  3. Study completion

  4. Started